Tachycardia resident survival guide: Difference between revisions
Steven Bellm (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
(3 intermediate revisions by one other user not shown) | |||
Line 15: | Line 15: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#FIRE: Focused Initial Rapid Evaluation|FIRE]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[{{PAGENAME}}#FIRE: Focused Initial Rapid Evaluation|FIRE]] | ||
|- | |- | ||
|} | |} | ||
Line 41: | Line 34: | ||
==Causes== | ==Causes== | ||
===Acute treatable causes of tachycardia=== | ===Acute treatable causes of tachycardia=== | ||
====H's==== | ====H's==== | ||
Line 55: | Line 48: | ||
*Tension pneumothorax | *Tension pneumothorax | ||
*Thrombosis, pulmonary | *Thrombosis, pulmonary | ||
*Thrombosis, coronary | *Thrombosis, coronary<ref name="pmid20956224">{{cite journal| author=Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW et al.| title=Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. | journal=Circulation | year= 2010 | volume= 122 | issue= 18 Suppl 3 | pages= S729-67 | pmid=20956224 | doi=10.1161/CIRCULATIONAHA.110.970988 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20956224 }} </ref> | ||
==FIRE: Focused Initial Rapid Evaluation== | ==FIRE: Focused Initial Rapid Evaluation== | ||
Line 95: | Line 88: | ||
❑ First dose: 6mg rapid IV push; follow with NS flush <br> | ❑ First dose: 6mg rapid IV push; follow with NS flush <br> | ||
❑ Second dose: 12mg if required}} | ❑ Second dose: 12mg if required}} | ||
{{familytree | | | {{familytree | | | | | |!| | | | | | | |!| | | | | | }} | ||
{{familytree | | {{familytree | | | | | |!| | | | | | | F03 | | | | | | F03 =<div style="text-align: left;"> | ||
❑ <u>Doses/details of synchronized cardioversion:</u> <br> | ❑ <u>Doses/details of synchronized cardioversion:</u> <br> | ||
: ❑ Narrow regular: 50-100 Joule <br> | : ❑ Narrow regular: 50-100 Joule <br> | ||
Line 105: | Line 98: | ||
: ❑ First dose: 6mg rapid IV push; follow with NS flush <br> | : ❑ First dose: 6mg rapid IV push; follow with NS flush <br> | ||
: ❑ Second dose: 12mg if required</div>}} | : ❑ Second dose: 12mg if required</div>}} | ||
{{familytree | |!| | | | | | | |!| | | |!| | | | | | }} | {{familytree | |,|-|-|-|^|-|-|-|.| | | |!| | | | | }} | ||
{{familytree | G01 | | | | | | G02 | {{familytree | |!| | | | | | | |!| | | |!| | | | | }} | ||
{{familytree | F01 | | | | | | F02 | | G03 | F01=[[Wide complex tachycardia|Wide complex tachycardia (≥120 ms)]]|F02=[[Narrow complex tachycardia|Narrow complex tachycardia (<120 ms)]] | G03=[[Hemodynamic instability|Proceed to Hemodynamic instability resident survival guide]]}} | |||
{{familytree | |!| | | | | | | |!| | | | | | | | | }} | |||
{{familytree | G01 | | | | | | G02 | | | | | G01=Consider expert consultation <br> Consider antiarrhythmic infusion <br> Consider adenosine only if monomorphic and regular|G02=Vagal maneuvers (No carotic sinus massage in patients with recent transient ischemic attack/stroke/ipsilateral significant carotid artery stenosis/carotid artery bruit)<ref name="pmid16418451">{{cite journal| author=Strickberger SA, Benson DW, Biaggioni I, Callans DJ, Cohen MI, Ellenbogen KA et al.| title=AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society. | journal=Circulation | year= 2006 | volume= 113 | issue= 2 | pages= 316-27 | pmid=16418451 | doi=10.1161/CIRCULATIONAHA.105.170274 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16418451 }} </ref> <br> Beta-Blockers or calcium channel blocker <br> Consider expert consultation <br> Adenosine if regular}} | |||
{{familytree | |!| | | | | | | |!| | | | | | | | | | }} | {{familytree | |!| | | | | | | |!| | | | | | | | | | }} | ||
{{familytree | H01 | | | | | | | {{familytree | |!| | | | | | | H02 | | | | | | | | | |H02=[[Narrow complex tachycardia resident survival guide|Proceed to Narrow complex tachycardia resident survival guide]]}} | ||
{{familytree | H01 | | | | | | | | | | | | | | | | | H01=<div style="text-align: left;"> | |||
❑ <u>Antiarrhythmic infusion for stable wide-QRS tachycardia:</u> <br> | ❑ <u>Antiarrhythmic infusion for stable wide-QRS tachycardia:</u> <br> | ||
: ❑ Procainamide IV Dose: <br> | : ❑ Procainamide IV Dose: <br> | ||
Line 123: | Line 120: | ||
: ❑ Sotalol IV Dose: <br> | : ❑ Sotalol IV Dose: <br> | ||
:: ❑ 100mg (1.5mg/kg) over 5 minutes. <br> | :: ❑ 100mg (1.5mg/kg) over 5 minutes. <br> | ||
:: ❑ Avoid if prolonged QT.</div> | :: ❑ Avoid if prolonged QT.</div>}} | ||
{{familytree | |!| | | | | | | | | | | | | | | | | | }} | {{familytree | |!| | | | | | | | | | | | | | | | | | }} | ||
{{familytree | I01 | | | | | | | | | | | | | | | | | I01=[[Wide complex tachycardia resident survival guide|Proceed to Wide complex tachycardia resident survival guide]]}} | {{familytree | I01 | | | | | | | | | | | | | | | | | I01=[[Wide complex tachycardia resident survival guide|Proceed to Wide complex tachycardia resident survival guide]]}} | ||
Line 132: | Line 130: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
</div> | |||
[[Category:Disease]] | [[Category:Disease]] | ||
Line 137: | Line 136: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Resident survival guide]] | [[Category:Resident survival guide]] | ||
Latest revision as of 00:23, 30 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: M.Umer Tariq [2]; Priyamvada Singh, M.D. [3]
Tachycardia resident survival guide Microchapters |
---|
Overview |
Classification |
Causes |
FIRE |
Overview
Tachycardia is a form of cardiac arrhythmia which refers to a rapid beating of the heart. By convention the term refers to heart rates greater than 100 beats per minute in the adult patient. Heart rate typically greater than 150 beats per minute in tachyarrhythmia.[1]
Classification
Algorithm based on the 2003 ACLS guidelines for the management of tachycardia.[2]
Causes
Acute treatable causes of tachycardia
H's
- Hypoxia
- Hypovolemia
- Hydrogen ion (acidosis)
- Hypo-/hyperkalemia
- Hypothermia
T's
- Toxins
- Tamponade (cardiac)
- Tension pneumothorax
- Thrombosis, pulmonary
- Thrombosis, coronary[3]
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
Tachycardia | |||||||||||||||||||||||||||||||||||||||
Pulse | No Pulse | ||||||||||||||||||||||||||||||||||||||
Evaluate and treat instability: | Pulseless VT or PEA | ||||||||||||||||||||||||||||||||||||||
❑ 12-lead ECG, don't delay therapy
❑ Ischemic chest discomfort | Proceed to ACLS Cardiac Arrest Algorithm | ||||||||||||||||||||||||||||||||||||||
Hemodynamic stable | Hemodynamic unstable | ||||||||||||||||||||||||||||||||||||||
Check QRS-duration | Synchronized cardioversion: ❑ Consider sedation | ||||||||||||||||||||||||||||||||||||||
❑ Doses/details of synchronized cardioversion:
❑ Adenosine IV dose:
| |||||||||||||||||||||||||||||||||||||||
Wide complex tachycardia (≥120 ms) | Narrow complex tachycardia (<120 ms) | Proceed to Hemodynamic instability resident survival guide | |||||||||||||||||||||||||||||||||||||
Consider expert consultation Consider antiarrhythmic infusion Consider adenosine only if monomorphic and regular | Vagal maneuvers (No carotic sinus massage in patients with recent transient ischemic attack/stroke/ipsilateral significant carotid artery stenosis/carotid artery bruit)[4] Beta-Blockers or calcium channel blocker Consider expert consultation Adenosine if regular | ||||||||||||||||||||||||||||||||||||||
Proceed to Narrow complex tachycardia resident survival guide | |||||||||||||||||||||||||||||||||||||||
❑ Antiarrhythmic infusion for stable wide-QRS tachycardia:
| |||||||||||||||||||||||||||||||||||||||
Proceed to Wide complex tachycardia resident survival guide | |||||||||||||||||||||||||||||||||||||||
Algorithm based on the 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.[3]
References
- ↑ Neumar, Robert W.; Otto, Charles W.; Link, Mark S.; Kronick, Steven L.; Shuster, Michael; Callaway, Clifton W.; Kudenchuk, Peter J.; Ornato, Joseph P.; McNally, Bryan; Silvers, Scott M.; Passman, Rod S.; White, Roger D.; Hess, Erik P.; Tang, Wanchun; Davis, Daniel; Sinz, Elizabeth; Morrison, Laurie J. (2010-11-02). "Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): –729-767. doi:10.1161/CIRCULATIONAHA.110.970988. ISSN 1524-4539. PMID 20956224.
- ↑ Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ; et al. (2003). "ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society". J Am Coll Cardiol. 42 (8): 1493–531. PMID 14563598.
- ↑ 3.0 3.1 Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW; et al. (2010). "Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S729–67. doi:10.1161/CIRCULATIONAHA.110.970988. PMID 20956224.
- ↑ Strickberger SA, Benson DW, Biaggioni I, Callans DJ, Cohen MI, Ellenbogen KA; et al. (2006). "AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society". Circulation. 113 (2): 316–27. doi:10.1161/CIRCULATIONAHA.105.170274. PMID 16418451.